On the development of novel cocaine-analogues for in vivo imaging of the dopamine transporter status

The present thesis is concerned with the development of novel cocaine-derived dopamine transporter ligands for the non-invasive exploration of the striatal and extra-striatal dopamine transporter (DAT) in living systems. The presynaptic dopamine transporter acquires an important function within the mediation of dopaminergic signal transduction. Its availability can serve as a measure for the overall integrity of the dopaminergic system. The DAT is upregulated in early Parkinson’s disease (PD), resulting in an increased availability of DAT-binding sites in the striatal DAT domains. Thereby, DAT imaging has become an important routine diagnostic tool for the early diagnosis of PD in patients, as well as for the differentiation of PD from symptomatically similar medical conditions. Furthermore, the dopaminergic system is involved in a variety of psychiatric diseases. In this regard, DAT-selective imaging agents may provide detailed insights into the scientific understanding of the biochemical background of both, the progress as well as the origins of the symptoms. DAT-imaging may also contribute to the determination of the dopaminergic therapeutic response for a given medication and thereby contribute to more convenient conditions for the patient. From an imaging point of view, the former demands a high availability of the radioactive probe to facilitate broad application of the modality, whereas the latter profits from short-lived probes, suitable for multi-injection studies. Therefore, labelling with longer-lived 18F-fluoride and in particular the generator nuclide 68Ga is worthwhile for clinical routine imaging. In contrast, the introduction of a 11C-label is a prerequisite for detailed scientific studies of neuronal interactions. The development of suitable DAT-ligands for medical imaging has often been complicated by the mixed binding profile of many compounds that that interact with the DAT. Other drawbacks have included high non-specific binding, extensive metabolism and slow accumulation in the DAT-rich brain areas. However, some recent examples have partially overcome the mentioned complications. Based on the structural speciality of these leads, novel ligand structures were designed and successfully synthesised in the present work. A structure activity relationship (SAR) study was conducted wherein the new structural modifications were examined for their influence on DAT-affinity and selectivity. Two of the compounds showed improvements in in vitro affinity for the DAT as well as selectivity versus the serotonin transporter (SERT) and norepinephrine transporter (NET). The main effort was focussed on the high-affinity candidate PR04.MZ, which was subsequently labelled with 18F and 11C in high yield. An initial pharmacological characterisation of PR04.MZ in rodents revealed highly specific binding to the target brain structures. As a result of low non-specific binding, the DAT-rich striatal area was clearly visualised by autoradiography and µPET. Furthermore, the radioactivity uptake into the DAT-rich brain regions was rapid and indicated fast binding equilibrium. No radioactive metabolite was found in the rat brain. [18F]PR04.MZ and [11C]PR04.MZ were compared in the primate brain and the plasma metabolism was studied. It was found that the ligands specifically visualise the DAT in high and low density in the primate brain. The activity uptake was rapid and quantitative evaluation by Logan graphical analysis and simplified reference tissue model was possible after a scanning time of 30 min. These results further reflect the good characteristics of PR04.MZ as a selective ligand of the neuronal DAT. To pursue 68Ga-labelling of the DAT, initial synthetic studies were performed as part of the present thesis. Thereby, a concept for the convenient preparation of novel bifunctional chelators (BFCs) was developed. Furthermore, the suitability of novel 1,4,7-triazacyclononane based N3S3-type BFCs for biomolecule-chelator conjugates of sufficient lipophilicity for the penetration of the blood-brain-barrier was elucidated.

Neuroökonomie = (Neuroeconomics): Neuronale Mechanismen ökonomischer Entscheidungen

Ökonomische Entscheidungen sind ebenso wie alltägliche Entscheidungen von der Aktivität von Hirnregionen abhängig, die zur Kontrolle verschiedener Teilschritte der Entscheidung beitragen. Aktivierung und Desaktivierung dieser Hirnregionen können mit Hilfe moderner bildgebender Verfahren, wie z.B. der funktionellen Magnet-Resonanz-Tomographie (fMRI) dargestellt werden. Die vorliegende Publikation gibt einen Überblick über das interdisziplinäre wissenschaftliche Arbeitsgebiet der „Neuroökonomie“ – einem jungen Forschungsfeld der Neurowissenschaften. Dieser Überblick ist auf sieben Hauptaspekte ökonomischer und finanzieller Entscheidungen fokusiert: 1. In welcher Weise werden ökonomische Parameter wie Wert und Nutzen einer Belohnung, Gewinn oder Verlust, Risiko und Ungewissheit in spezifischen Hirnregionen abgebildet? 2. In welcher spezifischen Weise tragen anatomisch definierte Areale des Gehirns zum Entscheidungsprozess bei? 3. In welcher Weise sind die Entscheidungsprozesse durch Läsion entscheidungsrelevanter Areale des Gehirns gestört? 4. In welcher Weise sind Hirnregionen, die an den Prozessen der Entscheidung beteiligt sind, miteinander vernetzt, um durch Interaktion die Entscheidung herbeizuführen? 5. In welcher Weise ist der Entscheidungsprozess von Persönlichkeitseigenschaften, von genetischen Variationen neuronaler Funktionen und von physiologischer Regulation, z.B. durch Hormone bestimmt? 6. In welcher Weise hängt der Entscheidungsprozess vom sozialen und kulturellen Umfeld des Entscheiders ab? 7. Auf welche Weise werden bei unvollständiger Information über die Optionen der Entscheidung Heuristiken oder Intuitionen genutzt, und in welcher Weise sind Entscheidungen durch Biases beeinflussbar? Der zentrale Teil dieser Publikation gibt einen zusammenfassenden Überblick (review) über die Ergebnisse neuroökonomischer Studien, die die fMRI-Technik nutzen (bis Juni 2010).